摘要
Statin is being used widely in patients who have ＇hyperlipidemia, coronary arterial disease （CAD）or other atherosclerosis diseases. Analysis shows that lowering plasma low density lipoprotein cholesterol C （LDL-C） level depends on the dose and various statins treated. LDL-C will achieve the maximal effects after 7-10 days administration.1＇2 Rosuvastatin is a hydrophilic statin, does not metabolize depending on cytochrome P 450 3A4, meaning less drug-drug interactions in cases of multipharmacy. 3 It shows to be the most potent of the available statins, with the greatest effect of lowering LDL-C in the Mercury I and II trials and the STELLAR trial,a＇5 decreasing LDL-C levels at approximately 50% of dose of atorvastatin.5 The recommended starting dose of rosuvastatin is 5-10 mg, according the individual patient＇s baseline LDL-C. Most patients get effective treatment after rosuvastatin therapy. However, few patients fail to get to the target range of LDL-C. One of possible mechanisms is statin escape.
Statin is being used widely in patients who have ＇hyperlipidemia, coronary arterial disease （CAD）or other atherosclerosis diseases. Analysis shows that lowering plasma low density lipoprotein cholesterol C （LDL-C） level depends on the dose and various statins treated. LDL-C will achieve the maximal effects after 7-10 days administration.1＇2 Rosuvastatin is a hydrophilic statin, does not metabolize depending on cytochrome P 450 3A4, meaning less drug-drug interactions in cases of multipharmacy. 3 It shows to be the most potent of the available statins, with the greatest effect of lowering LDL-C in the Mercury I and II trials and the STELLAR trial,a＇5 decreasing LDL-C levels at approximately 50% of dose of atorvastatin.5 The recommended starting dose of rosuvastatin is 5-10 mg, according the individual patient＇s baseline LDL-C. Most patients get effective treatment after rosuvastatin therapy. However, few patients fail to get to the target range of LDL-C. One of possible mechanisms is statin escape.
